Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Abstract

For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.

Keywords

• Hormone-sensitive Prostate Cancer
• Systemic Therapy
• Novel Hormonal Therapy
• Taxanes
• Triple Therapy